L1 Health and Blantyre Capital Acquire Remedica and Sun Wave Pharma

Dalrada Health (Sòlas) Acquires Remedi Med Spas

April 12, 2022

Healthcare Services

Dalrada Corporation's Dalrada Health division, operating under the Sòlas Rejuvenation + Wellness group, acquired Remedi Med Spas and its two Southern California locations in Coronado and Mission Hills from Dr. Rakhesh Guttikonda. The acquisition adds two clinics and staff to the North San Diego–based Sòlas platform as part of its regional expansion of wellness and aesthetic services.

Clarest Health Acquires Remedi SeniorCare

January 8, 2024

Healthcare Services

Clarest Health, a personalized medication management provider based in Vienna, Virginia, has acquired Remedi SeniorCare, a Towson, Maryland–based long-term and post-acute care pharmacy services provider. The acquisition—terms undisclosed—adds Remedi's proprietary automation technology (PAXIT) and customer portal (MyRemedi) to Clarest's medication management platform, expanding its technology capabilities and geographic footprint in the post-acute care market.

KKR and Impilo Acquire Immedica Pharma

January 24, 2025

Pharmaceuticals

KKR and Nordic healthcare investor Impilo have completed a joint acquisition of Stockholm-based Immedica Pharma, with Immedica management reinvesting alongside the new owners. Immedica is a commercial-stage pharmaceutical company focused on rare and specialty diseases (notably hematology, oncology and genetic/metabolic disorders) with ~€100m revenue and more than 120 employees; CVC Credit provided debt financing and Impilo used a single-asset continuation fund supported by secondary investors.

Curia Acquires LakePharma to Expand Biologics R&D and Manufacturing Capabilities

February 14, 2022

Biotechnology

Curia (formerly AMRI) has acquired LakePharma Inc., a US-based biologics contract research, development and manufacturing organization with operations in California, Massachusetts and Texas. The deal adds LakePharma's six facilities and ~235 employees to Curia's global network, creating expanded end-to-end capabilities from discovery through GMP manufacturing for biologics.

Lupin Healthcare Acquires Renascience Pharma Limited (UK)

April 2, 2025

Pharmaceuticals

Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, has acquired UK-based Renascience Pharma Limited, the sole supplier of four specialty branded products in the UK. The acquisition (reported at approximately £12.3 million) expands Lupin's branded specialty portfolio in the UK and strengthens its supply offerings to the NHS across infectious disease, ENT and cardiology/renal indications.

Medicure Inc. Acquires Marley Drug, Inc.

December 15, 2020

Healthcare Services

Medicure Inc., through its wholly-owned U.S. subsidiary Medicure Pharma Inc., agreed to acquire 100% of Marley Drug, Inc., a specialty mail-order pharmacy based in North Carolina, for an upfront USD $6.3 million plus contingent payments. Marley serves over 30,000 customers nationwide, generated approximately $7.0 million of revenue and more than $1.7 million of EBITDA for the 12 months ended October 31, 2020, and the acquisition expands Medicure's direct-to-patient distribution and specialty pharmacy capabilities in the United States.